

# Nelson B Watts

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7525434/nelson-b-watts-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25  
papers

4,953  
citations

19  
h-index

30  
g-index

30  
ext. papers

5,771  
ext. citations

9.8  
avg, IF

4.95  
L-index

#	Paper	IF	Citations
25	A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. <i>American Journal of Medicine</i> , <b>2000</b> , 109, 267-76	2.4	859
24	Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 73-9	59.2	847
23	Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. <i>American Journal of Medicine</i> , <b>1993</b> , 95, 557-67	2.4	310
22	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 157-66	5.6	290
21	Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 28-40	59.2	214
20	Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 44-51	5.6	176
19	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. <i>Endocrine Practice</i> , <b>2020</b> , 26, 1-46	3.2	164
18	Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. <i>American Journal of Medicine</i> , <b>1997</b> , 103, 468-76	2.4	124
17	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , <b>2016</b> , 22, 1111-8	3.2	115
16	Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 645-53	6.3	110
15	Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 22-30	3.5	93
14	Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 328-340	59.2	59
13	Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. <i>Obstetrics and Gynecology</i> , <b>2018</b> , 132, 147-160	4.9	59
12	2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 472-81	3.5	55
11	Postmenopausal Osteoporosis: A Clinical Review. <i>Journal of Women's Health</i> , <b>2018</b> , 27, 1093-1096	3	41
10	Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. <i>Obstetrics and Gynecology</i> , <b>2018</b> , 132, 1252-1264	4.9	26
9	Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2443-2452	5.6	23

8	Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , <b>2019</b> , 30, 1187-1194	5.3	15
7	Adverse bone effects of medications used to treat non-skeletal disorders. <i>Osteoporosis International</i> , <b>2017</b> , 28, 2741-2746	5.3	14
6	Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. <i>Obstetrics and Gynecology</i> , <b>2020</b> , 135, 1313-1326	4.9	13
5	History of etidronate. <i>Bone</i> , <b>2020</b> , 134, 115222	4.7	12
4	Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real-World Population. <i>JBMR Plus</i> , <b>2020</b> , 4, e10401	3.9	3
3	Bone Mineral Density Changes Associated With Pregnancy, Lactation, and Medical Treatments in Premenopausal Women and Effects Later in Life. <i>Journal of Women's Health</i> , <b>2021</b> , 30, 1416-1430	3	2
2	Letter to the Editor: "Risk for Infections During Treatment With Denosumab for Osteoporosis: a Systematic Review and Meta-Analysis". <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	1
1	Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial. <i>Osteoporosis International</i> , <b>2021</b> , 32, 55-61	5.3	1